Your browser is no longer supported. Please, upgrade your browser.
Settings
GHRS [NASD]
GH Research PLC
Index- P/E- EPS (ttm)- Insider Own42.54% Shs Outstand52.02M Perf Week-13.20%
Market Cap1.13B Forward P/E- EPS next Y-0.83 Insider Trans0.00% Shs Float30.53M Perf Month-21.61%
Income- PEG- EPS next Q-0.08 Inst Own54.90% Short Float3.16% Perf Quarter-12.49%
Sales- P/S- EPS this Y-43.80% Inst Trans2.98% Short Ratio9.57 Perf Half Y-
Book/sh5.54 P/B3.48 EPS next Y-83.70% ROA- Target Price32.33 Perf Year-
Cash/sh5.01 P/C3.85 EPS next 5Y- ROE- 52W Range12.38 - 30.43 Perf YTD0.05%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-26.24% Beta-
Dividend %- Quick Ratio63.80 Sales past 5Y- Gross Margin- 52W Low81.30% ATR3.54
Employees8 Current Ratio63.80 Sales Q/Q- Oper. Margin- RSI (14)49.33 Volatility22.20% 15.13%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume5.04 Prev Close19.26
ShortableYes LT Debt/Eq0.00 EarningsDec 06 BMO Payout- Avg Volume100.77K Price22.44
Recom1.50 SMA20-5.94% SMA506.03% SMA2008.54% Volume238,085 Change16.54%
Dec-06-21 07:10AM  
07:00AM  
Oct-27-21 04:50AM  
Sep-25-21 10:07AM  
Sep-23-21 05:25PM  
Jul-02-21 04:20PM  
Jun-25-21 01:23PM  
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.